Valuation : Ventyx Biosciences, Inc.

Market Cap 1B 866M 812M 741M 1.4B 96.02B 1.4B 9.63B 3.76B 48.47B 3.77B 3.69B 161B P/E 2025 *
-
P/E 2026 * -
Enterprise Value 1B 866M 812M 741M 1.4B 96.02B 1.4B 9.63B 3.76B 48.47B 3.77B 3.69B 161B EV / Sales 2025 *
-
EV / Sales 2026 * -
Free-Float
99.78%
Yield 2025 *
-
Yield 2026 * -

Last Transcript : Ventyx Biosciences, Inc.

1 day+0.14%
6 months+0.21%
Current year+55.04%
Current year 7.08
Extreme 7.08
25
1 year 2.26
Extreme 2.255
25
3 years 0.78
Extreme 0.783
38.2
5 years 0.78
Extreme 0.783
47.25
10 years 0.78
Extreme 0.783
47.25
Manager TitleAgeSince
President - 2026-03-03
Chief Tech/Sci/R&D Officer - 2024-01-31
Corporate Secretary - 2026-03-03
Director TitleAgeSince
Director/Board Member - 2026-03-03
Director/Board Member - 2026-03-03
Director/Board Member - 2026-03-03
Date Insider Type Main position Quantity % Market Cap.
3/4/26 Issuer sale

Chief Technology Officer

441,000 0.6145%
3/4/26 Issuer sale

Chief Financial Officer

287,013 0.4000%
3/4/26 Issuer sale

Chief Technology Officer

1,806,148 2.5169%
Change 5-day change 1-year change 3-year change Capi.($)
+0.14%-.--%+483.33%-56.82% 1B
-1.59%-3.35%+52.37%+93.70% 69.54B
-1.34%-0.75%+48.21%+91.86% 64.97B
+0.30%-0.69%+52.56%+10.23% 26.51B
-2.35%-5.75%-12.90%+448.54% 25.89B
-8.37%-12.43%+2.08%-16.71% 25.64B
-0.96%+10.36%+283.06%+436.50% 20.22B
-0.51%+0.23%+35.77%-18.70% 19.98B
-1.91%-4.37%+13.28%+535.19% 15.69B
-1.47%+0.68%+45.51%+143.08% 13.49B
Average -1.81%-1.70%+100.33%+166.69% 28.29B
Weighted average by Cap. -1.92%-1.50%+55.25%+150.77%

Financials

2025 *2026 *
Net sales - -
Net income - -175.76 -151.46 -142.01 -129.63 -244.2 -16.8K -244.98 -1.68K -657.34 -8.48K -659.91 -645.55 -28.12K
Net Debt - -
Logo Ventyx Biosciences, Inc.
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its lead portfolio of NOD-like receptor protein 3 (NLRP3) inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase II development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase II development for neurodegenerative and cardiometabolic diseases. Its inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase II clinical trials. Tamuzimod is a sphingosine 1 phosphate receptor (S1P1R) modulator in development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is a selective allosteric tyrosine kinase type 2 (TYK2) inhibitor in Phase II development for the treatment of moderately to severely active Crohn’s disease.
Employees
83
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. VTYX Stock